Regístrese
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Un consenso latinoamericano sobre el síndrome del intestino irritable
Información de la revista
Vol. 27. Núm. 5.
Páginas 325-343 (Enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. 5.
Páginas 325-343 (Enero 2004)
DOI: 10.1016/S0210-5705(03)70470-1
Acceso a texto completo
Un consenso latinoamericano sobre el síndrome del intestino irritable
Visitas
13926
J. Valenzuelaa,
Autor para correspondencia
jvalenzu@mi-mail.cl

Correspondencia: Dr. J. Valenzuela. Departamento de Gastroenterología. Hospital Clínico de la Universidad de Chile. Avda. Santos Dumont, 999. Independencia. Chile
, J. Alvaradob, H. Cohenc, A. Damiaod, C. Francisconie, L. Frugonef, J.C. Gonzálezg, A. Hernándezh, B. Iadec, M.H. Itaqui Lopese, R. Latorrea, J. Pradod, P. Moraes-Filhod, M. Schmulsoni, L. Soiferj, M.A. Valdovinosi, E. Vescok, A. Zalarj
a Facultad de Medicina. Hospital Clínico. Universidad de Chile. Santiago. Chile
b Facultad de Medicina. Universidad Javeriana. Bogotá. Colombia
c Hospital de Clínicas Dr. Manuel Quintela. Montevideo. Uruguay
d Departamento de Gastroenterología. Facultad de Medicina. Universidad de Sao Paulo. Brasil
e Departamento de Medicina Interna. Facultad de Medicina. Universidad Federal de Rio Grande do Sul. Porto Alegre. Brasil
f Facultad de Medicina. Universidad de Guayaquil. Ecuador
g Escuela de Medicina. Universidad Central de Venezuela. Caracas. Venezuela
h Guatemala, Centro América y Caribe
i Departamento de Gastroenterología. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Ciudad de México. México
j Servicio de Gastroenterología del CEMIC. Hospital Juan A. Fernández. Buenos Aires. Argentina
k Universidad Particular San Martín de Porres. Lima. Perú
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome in North America.
Amer J Gastroenterol, 97 (2002), pp. S1-S5
[2.]
A.P. Manning, W.G. Thompson, K.W. Heaton, et al.
Towards a positive diagnosis of the irritable bowel.
Br Med J, 2 (1978), pp. 653-654
[3.]
W.G. Thompson, G.F. Longstreth, D.A. Drossman, et al.
Functional bowel disorders and functional abdominal pain.
Gut, 45 (1999), pp. 43-47
[4.]
S.J. Vanner, W.T. Depew, W. Paterson, L.R. Lacosta, A.G. Groll, J.B. Simon, et al.
Predictive value of the Roma criteria for diagnosing the irritable bowel syndrome.
Am J Gastroenterol, 94 (1999), pp. 2912-2917
[5.]
W.G. Thompson.
Irritable bowel syndrome: prevalence, prognosis and consequences.
CMAJ, 134 (1986), pp. 111-113
[6.]
G.F. Longstreth, G. Wolde-Tsadik.
Irritable bowel-type symptoms in HMO examinees: prevalence, demographics and clinical correlates.
Dig Dis Sci, 38 (1993), pp. 1581-1589
[7.]
G. Bommelaer, M. Rouch, M. Dapoigny, D. Pais, P. Loisy, M. Gaylino, et al.
Epidemiology of functional bowel disorders in apparently healthy people.
Gastroenterol Clin Biol, 10 (1986), pp. 7-12
[8.]
G.W. Welch, E.W. Pomare.
Functional gastrointestinal symptoms in a Wellington community sample.
NZ Med J, 103 (1990), pp. 418-420
[9.]
L. Kay, T. Jorgensen, K.H. Jensen.
The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors.
J Intern Med, 236 (1994), pp. 23-30
[10.]
W. Bi-Zhen, P. Qi-Ying.
Functional bowel disorders in apparently healthy Chinese people.
Chinese J Epidemiol, 9 (1988), pp. 345-349
[11.]
D.A. Drossman, Z. Li, E. Andruzzi, et al.
US householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact.
Dig Dis Sci, 38 (1993), pp. 1569-1580
[12.]
M.J. Zuckerman, L.G. Guerra, D.A. Drossman, J.A. Foland, G.G. Gregory.
Comparison of bowel patterns in Hispanics and non-Hispanic whites.
Dig Dis Sci, 40 (1995), pp. 1761-1769
[13.]
A.P.S. Hungin, P.J. Whorwell, J. Tack, F. Mearin.
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40.000 subjects.
Aliment Pharmacol Ther, 17 (2003), pp. 643-650
[14.]
C.M. Mitchell, D.A. Drossman.
Survey of the AGA membership relating to patients with functional gastrointestinal disorders.
Gastroenterology, 92 (1987), pp. 1282-1284
[15.]
N.J. Talley, A.R. Zinsmeister, C. Van Dyke, L.J. Melton III.
Epidemiology of colonic symptoms and the irritable bowel syndrome.
Gastroenterology, 101 (1991), pp. 927-934
[16.]
R. Jones, S. Lydeard.
Irritable bowel syndrome in the general population.
BMJ, 304 (1992), pp. 87-90
[17.]
B.L.J. Mendis, B.C. Wijesiriwardena, J.H.R. Sheriff, K. Dharmadasa.
Irritable bowel syndrome.
Ceylon Med J, 27 (1982), pp. 171-181
[18.]
D.T. Sobral, K.S. Vidigal, K. Farias e Silva.
Síntomas digestivos em jovens: inquérito em estudantes de medicina.
Arq Gastroenterol (Sao Paolo), 28 (1991), pp. 27-32
[19.]
F.A. Quilici, SB. André.
Um consenso nacional: síndrome do intestino irritável.
[20.]
L.A. Ángel, A. Amaya, C. Perilla, A. Góngora, A. Sánchez, C. Bohórquez, et al.
Prevalencia del síndrome de intestino irritable y factores asociados.
Acta Med Col, 22 (1997), pp. 219-224
[21.]
I. Huerta, M.A. Valdovinos, M. Schmulson.
Irritable bowel syndrome in México.
Dig Dis, 19 (2001), pp. 251-257
[22.]
M.A. Tanimoto, M. Schmulson, D. Ramírez, M.A. Valdovinos.
Prevalencia de trastornos funcionales digestivos en estudiantes de medicina.
Rev Gastroenterol Mex, 60 (1995), pp. 57
[23.]
R. Toma, B. Iade.
Frecuencia del síndrome de intestino irritable en una población de Montevideo. Montevideo: Hospital de Clínicas «Dr Manuel Quintela», Escuela de Graduados, Clínica de Nutrición y Digestivo.
Profesor D.r. Elbio Zevallos, agosto de, (2000),
[24.]
M.J. Schmulson, M.A. Valdovinos.
Utilización de recursos médicos por los pacientes con síndrome de intestino irritable en un hospital de tercer nivel.
Rev Gastroenterol Mex, 63 (1998), pp. 6-10
[25.]
M. Schmulson, J.M. Remes, T. Olivas, M.A. Valdovinos, C. Hinojosa, L. Chang, et al.
Clinical characteristics and QOL in IBS patients from Mexico and the USA: are they different?.
Gastroenterology, 124 (2003), pp. A395
[26.]
J.F. Fieling.
Surgery and the irritable bowel syndrome: the singer as well as the song.
J Ir Med, 76 (1988), pp. 33-34
[27.]
J.M. Remes, M.A. Valdovinos, C. Hinojosa, M.J. Schmulson.
IBS patients differ according to age: self-reported symptom severity is related.
Am J Gastroenterol, 98 (2003), pp. 5268
[28.]
C.F. Francisconi, U. Meneghelli, F. Quilici, M.T. Haddad, S. André.
A comparison of how gastroenterologists (GE) and internists (INT) evaluate patients with irritable bowel syndrome (IBS).
Gut, 45 (1999), pp. A340
[29.]
M.C. Bojórquez, A. Larrosa, E.O. Martínez.
Dolor abdominal crónico (DAC) en niños: ¿síndrome de intestino irritable (SII) versus dispepsia no ulcerosa (DNU)?.
Rev Gastroenterol Méx, 65 (2000), pp. A52
[30.]
D.A. Drossman, W.E. Whitehead, M. Camilleri.
Irritable bowel syndrome: a technical review for practice guideline development.
Gastroenterology, 112 (1997), pp. 2120-2137
[31.]
H. Mertz.
Review article: visceral hypersensitivity.
Aliment Pharmacol Ther, 17 (2003), pp. 623-633
[32.]
H. Mertz.
Altered CNS processing of visceral pain in IBS.
Irritable bowel syndrome diagnosis and treatment, pp. 55-68
[33.]
M. Camilleri, M-G. Choi.
Irritable bowel syndrome.
Aliment Pharmacol Ther, 11 (1997), pp. 3-15
[34.]
D.H.S. Silverman, J.A. Munakata, H. Ennes, et al.
Regional cerebral activity in normal and pathologic perception of visceral pain.
Gastroenterology, 112 (1997), pp. 64-72
[35.]
R. Quera, J. Valenzuela.
Hipersensibilidad visceral: un concepto a nuestro alcance.
Rev Med Chile, 131 (2003), pp. 85-92
[36.]
M.J. Schmulson, M.A. Valdovinos, P. Milke.
Chili pepper and rectal hyperalgesia in irritable bowel syndrome.
Am J Gastroenterol, 98 (2003), pp. 1214-1215
[37.]
J. Serra, F. Azpiroz, J.R. Malagelada.
Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome.
Gut, 48 (2001), pp. 14-19
[38.]
R.C. Spiller.
Postinfectious irritable bowel syndrome.
Gastroenterology, 124 (2003), pp. 1662-1671
[39.]
D.A. Drossman.
Psychosocial aspects of the functional gastrointestinal disorders.
Neurogastroenterology, pp. 33-40
[40.]
D.A. Drossman, J. Leserman, G. Nachman, et al.
Sexual and physical abuse in women with functional or organic gastrointestinal disorders.
Ann Intern Med, 113 (1990), pp. 828-833
[41.]
N.J. Talley, S.L. Fett, A.R. Zinsmeister, L.J. Melton III.
Gastrointestinal tract symptoms and self-report abuse: a population based study.
Gastroenterology, 107 (1994), pp. 1040-1049
[42.]
W.E. Whitehead, O.S. Palsson.
Is pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception.
Gastroenterology, 115 (1998), pp. 1263-1271
[43.]
F. Creed.
Psychopatology of the functional disorders of the gut.
Functional disorders of the gut,
[44.]
B.A. Hahn, L.J. Kirchdoerfer, S. Fullerton, et al.
Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization, and quality of life.
Aliment Pharmacol Ther, 11 (1997), pp. 553-559
[45.]
R.F. Yacavone, I.I.I. Locke GR, D.T. Provenzale, G.M. Eisen.
Quality of Life measurement in gastroenterology: what is available?.
Am J Gastroenterol, 96 (2001), pp. 285-297
[46.]
M. Schmulson, O.Y. Lee, L. Chang, et al.
Symptom differences in moderate to severe IBS patients based on predominant bowel habit.
Am J Gastroenterol, 94 (1999), pp. 2929-2935
[47.]
M.A. Testa, D.C. Simonson.
Assessment of quality of life outcomes.
N Engl J Med, 334 (1966), pp. 835-840
[48.]
I.K. Wiklund, H. Glise.
Quality of life in different gastrointestinal conditions.
Eur J Surg Suppl, 582 (1998), pp. 56-61
[49.]
A.L. Steward, S. Greenfield, R.D. Hays, et al.
Functional status and well being of patients with chronic conditions: results from the medical outcomes study.
JAMA, 262 (1989), pp. 907-913
[50.]
J.P.P. Moraes-Filho.
Doenças funcionais do aparelho digestivo: a importância 2 distúrbios emocionais na gênese dos sintomas.
Rev Bras Med, 51 (1994), pp. 1395-1404
[51.]
H.B. El-Serag.
Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life.
Rev Gastroenterol Dis, 3 (2003), pp. 3-11
[52.]
H.B. El-Serag, K. Olden, D. Bjorkman.
Health-related quality of life among persons with irritable bowel syndrome: a systematic review.
Aliment Pharmacol Ther, 16 (2002), pp. 1171-1185
[53.]
D.A. Drossman, W.E. Whitehead, B.B. Toner, et al.
What determines severity among patients with painful functional bowel disorders.
Am J Gastroenterol, 95 (2000), pp. 974-980
[54.]
N.E. Wells, B.A. Hahn, P.J. Whorwell.
Clinical economical review: irritable bowel syndrome.
Aliment Pharmacol Ther, 11 (1997), pp. 1019-1030
[55.]
P.P. Patel, A. Petita, R. Fogel, et al.
The economic impact of irritable bowel syndrome in a managed care setting.
J Clin Gastroenterol, 35 (2000), pp. 14-20
[56.]
N.J. Talley, S.F. Philips, L.J. Melton, et al.
Diagnostic value of the Manning criteria in irritable bowel syndrome.
Gut, 31 (1990), pp. 77
[57.]
M.W. Schmulson, L. Chang.
Diagnostic approach to the patient with irritable bowel syndrome.
Am J Med, 107 (1999), pp. 205
[58.]
Thompson WG, Longstreth G, Drossman DA, et al. En: Rome II: the functional gastrointestinal disorders. 2nd ed. p. 335-408.
[59.]
R.B. Lynn, L.S. Friedman.
Irritable bowel syndrome.
N Engl J Med, 329 (1993), pp. 1940
[60.]
E.T. Swarbrick, L. Bat, J.E. Hegarty, et al.
Site of pain from the irritable bowel.
Lancet, 2 (1980), pp. 443
[61.]
A.M. Connell, C. Hilton, G. Irvine, et al.
Variation of bowel habits in two population samples.
Br Med J, 2 (1965), pp. 1095
[62.]
P.J. Whorwell, M. McCallum, F.H. Creed, C.T. Roberts.
Non-colonic features of irritable bowel syndrome.
Gut, 27 (1986), pp. 37-40
[63.]
A.M. White, W.H. Stevens, A.R. Upton, et al.
Airway responsiveness to inhaled metacholine in patients with irritable bowel syndrome.
Gastroenterology, 100 (1991), pp. 68-74
[64.]
J.I. Hudson, D.L. Goldenberg, H.G. Pope, et al.
Comorbidity of fibromyalgia with medical and psyquiatric disorders.
Am J Med, 92 (1992), pp. 363
[65.]
S.J. Vanner, W.T. Depew, W.G. Paterson, et al.
Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome.
Am J Gastroenterol, 94 (1999), pp. 2912
[66.]
L.J. Brandt, D. Bjorkman, M.B. Fennerty, et al.
Systematic review on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. S7-S26
[67.]
D.A. Drossman, W.E. Whitehead, M. Camillieri.
Irritable bowel syndrome: a technical review for practice guideline development.
Gastroenterology, 112 (1997), pp. 2120-2137
[68.]
W. Curioso, D. Mendoza.
Prevalencia y asociación de la dispepsia y el síndrome de intestino irritable en una comunidad de la selva peruana.
Rev Gastroent Perú, 22 (2002), pp. 129-140
[69.]
W.J. Katon, M. Von Korff, E. Lin.
Panic disorder: relationship to high medical utilization.
Am J Med, 92 (1992), pp. 7S
[70.]
D.A. Drossman, W.G. Thompson.
The irritable bowel syndrome: review and a graduated multi-component treatment approach.
Ann Intern Med, 116 (1992), pp. 1009
[71.]
R.A. Awad, V.H. Cordova, M. Dibildox, et al.
Reduction of post prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.
Acta Latinoamer Gastroenterol, 27 (1997), pp. 247-251
[72.]
R. Bulat, C. Caldarelli, G. Tougas.
Therapeutic utility of antispasmodics in IBS.
Irritable bowel syndrome diagnosis and treatment, pp. 173-178
[73.]
R. Awad, M. Dibildox, F. Ortiz.
The irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized, double blind placebo-controlled trial.
Acta Gastroenterol Latinoam, 25 (1995), pp. 137-144
[74.]
T. Poynard, S. Naveau, B. Mory, J.C. Chaput.
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.
Aliment Pharmacol Ther, 8 (1994), pp. 499-510
[75.]
T. Poynard, C. Regimbeau, Y. Benhamou.
Meta-analysis of smooth muscle relevants in the treatment of irritable bowel syndrome.
Aliment Pharm Ther, 15 (2001), pp. 355-361
[76.]
J. Jailwala, T. Imperiale, K. Kroenke.
Pharmacologic management of IBS. A systematic review of randomized controlled trials.
Ann Intern Med, 133 (2000), pp. 136-147
[77.]
S.J.O. Veldhuyzen van Zante, N.J. Talley, P. Bytzer, K.B. KLein, O.J. Whorwell, A.R. Zinsmeister.
Design of treatment trials for functional gastroeintestinal disorders.
Gut, 45 (1999), pp. 1169-1177
[78.]
R. Akehurst, E. Kaltenhaler.
Treatment of irritable bowel syndrome: review of randomized controlled trials.
Gut, 48 (2001), pp. 272-282
[79.]
N. Talley.
Pharmacologic therapy for the irritable bowel syndrome.
Am J Gastroenterol, 98 (2003), pp. 750-758
[80.]
D.P. Burkitt, A.R.P. Walker, N.S. Painter.
Effect of dietary fiber on stools and transit times and its role in the causation of disease.
Lancet, 2 (1971), pp. 1408-1411
[81.]
E. Bright-See, G.E. MacKeown-Eysson.
Estimation of per capita crude and dietary fiber supply in 38 countries.
Am J Clin Nutr, 39 (1984), pp. 821-829
[82.]
R. Vincent, A. Roberts, M. Frier.
Effect of bran particle size on gastric emptying and bowel transit in humans: a scintigrafic study.
Gut, 37 (1995), pp. 216-219
[83.]
A. MacIntyre, R.M. Vincent, A.C. Perkins, R.C. Spiller.
Effect of bran, ispaghula and inert plastic particles on gastric emptying and small bowel transit in humans.
Gut, 40 (1997), pp. 223-227
[84.]
G.F. Longstreth, D.D. Fox, L. Youkeles, A.B. Forsythe, D.A. Wolochow.
Psyllium therapy in the irritable bowel syndrome. A double-blind trial.
Ann Intern Med, 95 (1981), pp. 53-56
[85.]
M. Tomás, R. Anon, M. Mínguez.
The efficacy of Platago ovata as a regulator of intestinal transit. A double-blind study compared to placebo.
Rev Esp Enferm Dig, 82 (1992), pp. 511-514
[86.]
S. Arffmann, J.R. Andersen, J. Hegnhoj, D.M.O. Schaffalitzky, N.B. Mogensen.
The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind crossover study.
Scand J Gastroenterol, 20 (1985), pp. 295-298
[87.]
J. Snook, H.A. Shepherd.
Bran supplementation in the treatment of the irritable bowel syndrome.
Aliment Pharmacol Ther, 8 (1994), pp. 511-514
[88.]
M.R. Lucey, M.L. Clark, J. Lowndes, A.M. Dawson.
Is bran efficacious in the irritable bowel syndrome? A double blind placebo controlled crossover study.
Gut, 28 (1987), pp. 221-225
[89.]
P.B. Mortensen, J.R. Andersen, S. Arffmann, E. Krag.
Shortchain fatty acids and the irritable bowel syndrome: the effect of wheat bran.
Scand J Gastroenterol, 22 (1987), pp. 185-192
[90.]
J. Soltoft, B. Krag, E. Gudmand-Hoyer, E. Kristensen, H.R. Wulff.
A double-blind trial of the effect of wheat bran on symptoms of the irritable bowel syndrome.
Lancet, 1 (1976), pp. 270-272
[91.]
S. Fowlie, M.A. Eastwood, R. Prescott.
The irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fiber supplementation.
J Psychosom Res, 36 (1992), pp. 175-180
[92.]
I.J. Cook, E.J. Irvine, D. Campbell, S. Shannon, S.N. Reddy, S.M. Collins.
Effect of dietary fiber on symptoms and rectosigmoid motility in patients with the irritable bowel syndrome. A controlled crossover study.
Gastroenterology, 98 (1990), pp. 66-72
[93.]
P.P. Toskes, K.L. Connery, T.W. Ritchey.
Calcium polycarbophil compared with placebo in the irritable bowel syndrome.
Aliment Pharmacol Ther, 7 (1993), pp. 87-92
[94.]
A. Jalihal, G. Kurian.
Ispaghula therapy in the irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction.
J Gastroenterol Hepatol, 5 (1990), pp. 507-513
[95.]
A. Prior, P.J. Whorwell.
Double blind study of ispaghula in the irritable bowel syndrome.
Gut, 28 (1987), pp. 1510-1537
[96.]
T. Hallgren, S. Fath, D.S. Delbro, et al.
Loperamide improves sphincter function and continence after restorative proctocolectomy.
Dig Dis Sci, 39 (1994), pp. 2612-2618
[97.]
E. Ayala, R. Barúa León.
Asociación entre síndrome de intestino irritable y síndrome depresivo.
Rev Gastroent Perú, 21 (2001), pp. 198-204
[98.]
M. Read, N.W. Read, D.C. Barber, H.L. Duthie.
Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency.
Dig Dis Sci, 27 (1982), pp. 807-814
[99.]
R.A. Awad, F. Llorens, A.L. Camelo, M. Sánchez.
A randomized double-blind placebo-controlled trial of lidamidin HCL in irritable bowel syndrome.
Acta Gastroenterol Latinoam, 30 (2000), pp. 169-175
[100.]
A. Rodríguez, T. Valdez, F. Llorens.
Tratamiento del colon irritable con lidamidina y psicoterapia de apoyo.
Rev Gastroenterol Mex, 62 (1997), pp. 7-13
[101.]
M. Camilleri, D-Y Kim, S. McKinzie, et al.
Clonidine in diarrea- predominant irritable bowel syndrome: a ramdomized, placebo-controlled, dose response study.
Gastroenterology, 122 (2002), pp. A59
[102.]
I.G. Egbunike, BJ. Chaffeé.
Antidepressants in the management of chronic pain syndromes.
Pharmacotherapy, 10 (1990), pp. 262-270
[103.]
K.B. Klein.
Controlled treatment trials in the irritable bowel syndrome: a critique.
Gastroenterology, 95 (1988), pp. 232-241
[104.]
R.E. Clouse, P.J. Lustman, R.A. Geisman, et al.
Antidepressant therapy in 138 patients with irritable bowel syndrome: a five year clinical experience.
Aliment Pharmacol Ther, 8 (1994), pp. 409-416
[105.]
J. Jailwala, P.F. Imperiale, K. Kroenke, et al.
Pharmacology treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials.
Ann Int Med, 133 (2000), pp. 136-147
[106.]
J.L. Jackson, P.G. O'Malley, G. Tomkins, et al.
Treatment of functional gastrointestinal disorders with antidepressant medications. A meta-analysis.
Am J Med, 108 (2000), pp. 65-72
[107.]
American College of Gastroenterology, Functional Gastrointestinal Disorders Task Force.
Evidence-based position statement on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. 1S-5S
[108.]
N. Talley.
Serotoninergic neuroenteric modulators.
Lancet, 358 (2001), pp. 2061-2064
[109.]
L.X. Cubeddu.
Serotonin mechanisms in chemoterapy-induced emesis in cancer patients.
Oncology, 53 (1996), pp. 18-25
[110.]
J.J. Galligan.
Motility and pharmacologic therapies. Schuster atlas of gastrointestinal motiliy in health and disease 2 nd e.d. BC Decker Inc.
Hamilton, (2002), pp. 399-410
[111.]
M. Camilleri, A.R. Northcutt, S. Kong.
Efficacy and safety of alosetron in women with irritable bowel syndrome.
[112.]
K. Olden, R.G. DeGarmo, P. Jhingran, B. Bagby, C. Decker, M. Markowitz, et al.
Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Amer J Gastroenterol, 97 (2002), pp. 3139-3145
[113.]
S. Caras, G. Krause.
Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome.
Gastroenterology, 120 (2001), pp. A217
[114.]
J. Bockaert, L. Fagni, A. Dumuis.
5HT4 receptors: an update.
Handbook Exp Pharmacol, 129 (1997), pp. 439-474
[115.]
J. Fioramonti, M. Million, L. Bueno.
Investigations on a 5-HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying [resumen].
Gastroenterology, 114 (1998), pp. A752
[116.]
H-J Pfannkuche, T. Jul, R. Gamse, D. Hoyer, H. Mattes, K-H. Buchheit.
The properties of the new prokinetically active drug. SDZ HTF 919 [resumen].
Neurogastroenterol Mot, 7 (1995), pp. 280
[117.]
C.M. Prather, M. Camilleri, A.R. Zinsmeister, et al.
Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome.
Gastroenterology, 118 (2000), pp. 463-468
[118.]
S. Muller-Lissner, I. Fumagalli, K.D. Bardhan, et al.
Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
Aliment Pharmacol Ther, 15 (2001), pp. 1655-1666
[119.]
M.P. Lefkowitz, Y. Shi, C. Schmitt, et al.
The 5HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome [resumen 396].
Am J Gastroenterol, 94 (1999), pp. 2676
[120.]
J. Novick, P. Miner, R. Krause, K. Glebas, H. Bliesath, G. Ligozio, et al.
A randomized, double blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
Aliment Pharmacol Ther, 16 (2002), pp. 1877-1888
[121.]
J. Kellow, O. Lee, F.Y. Chang, S. Thongsawat, M.Z. Mazlam, H. Yuen, et al.
An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
Gut, 52 (2003), pp. 671-676
[122.]
H. Nyhlin, C. Bang, L. Elsborg, et al.
Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population.
Gastroenterology, 124 (2003), pp. A389
[123.]
Study #307 Data on file. Novartis Pharmaceuticals Corporation.
[124.]
M. Camilleri.
Management of the irritable bowel syndrome.
Gastroenterology, 120 (2001), pp. 652-668
[125.]
The Latin America Investigation Group of Tegaserod: Uzcanga L Cohen V.
Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (I.B.S.
-C) Gastroenterology, 123 (2003), pp. A571
[126.]
D.A. Drossman, M. Camilleri, E. Mayer, et al.
AGA technical review on irritable bowel syndrome.
Gastroenterology, 123 (2002), pp. 2108-2131
[127.]
M. Camilleri.
Management of the irritable bowel syndrome.
Gastroenterology, 120 (2001), pp. 652-668
[128.]
W.E. Whitehead, M.D. Crowell, J.C. Robinson, et al.
Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared to subjects without bowel dysfunction.
Gut, 33 (1992), pp. 825-830
[129.]
L.J. Brandt, D. Bjorkman, M.B. Fennerty, et al.
Systematic review on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. 1-26
[130.]
S.J.O. Veldhuyzen van Zanten, N.J. Talley, P. Bytzer, et al.
Design of treatment trials for functional gastrointestinal disorders.
Gut, 45 (1999), pp. 1169-1177
[131.]
D.A. Drossman, B. Toner, W. Whitehead, et al.
A multi-center randomized trial of cognitive-behavioral treatment (CBT) versus education (EDU) in moderate to severe functional bowel disorder (FBD).
Gastroenterology, 124 (2003), pp. A530
[132.]
R. Lea, L.A. Houghton, E.L. Calvert, et al.
Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome.
Aliment Pharmacol Ther, 17 (2003), pp. 635-642
[133.]
W.M. Gonzalkorale, V. Miller, A. Afzal, P.J. Whorwell.
Long term benefits of hypnotherapy for irritable bowel syndrome.
Gut, 52 (2003), pp. 1623-1629
[134.]
E. Quigley, L. O'Mahony, J. McCarthy, P. Kelly, J.K. Collins, F. Shanahan, et al.
Probiotics for the irritable bowel syndrome (IBS): a randomized, double blind, placebo-controlled comparison of lactobacillus and bifidobacterium strains.
Gastroenterology, 122 (2002), pp. A59
[135.]
M.A. O'Sullivan, C.A. O'Morain.
Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo- controlled crossover study.
Dig Liver Dis, 32 (2000), pp. 302-304
[136.]
N.W. Read, J.L. Abitbol, K.D. Bardhan, P.J. Whorwell, B. Fraitag.
Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.
Gut, 41 (1997), pp. 664-668
[137.]
M. Dapoigny, J.L. Abitbol, B. Fraitag.
Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.
Dig Dis Sci, 40 (1995), pp. 2244-2249
[138.]
J.R. Mathias, M.H. Clench, T.L. Abell, et al.
Effect of leuprolide acetate in treatment of abdominal pain and nausea in pre menopausal women with functional bowel disease: a doubleblind, placebo-controlled, randomized study.
Dig Dis Sci, 43 (1998), pp. 1347-1355
[139.]
Farthing MJG.
New drugs in the management of the irritable bowel syndrome.
Drugs, 56 (1998), pp. 11-21
[140.]
A. Bensoussan, N.J. Talley, M. Hing, R. Menzies, A. Guo, M. Ngu.
Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.
JAMA, 280 (1998), pp. 1585-1589
[141.]
M. Pittler, E. Ernst.
Peppermint for irritable bowel syndrome: a critical review and metaanalysis.
Am J Gastroenterol, 93 (1998), pp. 1131-1135
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.